TY - JOUR T1 - Autoantigen characterization in the lower esophageal sphincter muscle of patients with achalasia JF - medRxiv DO - 10.1101/2021.10.01.21264384 SP - 2021.10.01.21264384 AU - Ángel Priego-Ranero AU - Ghislain Opdenakker AU - Norma Uribe-Uribe AU - Diana Aguilar-León AU - Carlos A. Nuñez-Álvarez AU - Diego F. Hernández-Ramírez AU - Elizabeth Olivares-Martínez AU - Enrique Coss-Adame AU - Miguel A. Valdovinos AU - Janette Furuzawa-Carballeda AU - Gonzalo Torres-Villalobos Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/01/2021.10.01.21264384.abstract N2 - OBJECTIVE To characterize in sera anti-myenteric autoantibody profiles and in tissues MMP-9 proteoforms towards the identification of possible autoantigenic proteins in the muscle of the lower esophageal sphincter (LES) of achalasia patients.METHODS Biopsies of the LES muscle from 36 achalasia patients, 6 esophagogastric junction outflow obstruction (EGJOO) patients, and 16 transplant donors (TD) were compared in a blind cross-sectional study. Histological characteristics such as inflammation, fibrosis, presence of ganglion cells, cells of Cajal, GAD65, PNMA2, S100, P substance, and MMP-9 proteforms in tissue were assessed by H&E and Picro-Sirius Red stainings, and immunohistochemistry analysis. Antineuronal antibodies (amphiphysin, CV2, and PNMA2 (Ma2/Ta)), onconeural antigens (Ri, Yo, and Hu), recoverin, SOX-1, titin, zic4, GAD65, and Tr (DNER) were evaluated by immunoblot/line assay.RESULTS Tissue of achalasia patients had heterogeneous inflammatory infiltrates with fibrosis and contrasting higher levels of activated MMP-9 compared with EGJOO and TD. Moreover, lower ganglion cell percentages and cell of Cajal percentages were determined in esophageal tissues of achalasia patients vs. TD. In addition, tissue of achalasia patients had higher GAD65 and PNMA2 protein expression vs. EGJOO. Unexpectedly, these proteins were absent in TD tissue. S100 and P substance had similar expression levels in tissues of achalasia patients vs.TD and EGJOO. Most of the achalasia sera had anti-GAD65 (83%) and anti-PNMA2 (90%) autoantibodies vs. EGJOO (17% and 33%, respectively) and healthy volunteers (10% and 0%, respectively).CONCLUSION Tissue-specific ectopic expression of GAD65 and PNMA/Ta2 and active MMP-9, associated with the presence of specific autoantibodies directed against these proteins, might participate in the pathophysiology of achalasia triggering and/or perpetuating autoimmune disease.WHAT YOU NEED TO KNOW?BACKGROUND AND CONTEXTBACKGROUND AND CONTEXT Achalasia is a primary esophageal motility disorder associated with a selective loss of inhibitory neurons in the myenteric esophageal plexus.An inflammatory/autoimmune response seems involved in pathophysiology.NEW FINDINGSNEW FINDINGS Most of the achalasia sera have anti-GAD65 and anti-PNMA2 autoantibodies vs. EGJOO and healthy volunteers.Esophageal tissues of achalasia patients have higher ectopic GAD65 and PNMA2 protein expression vs. EGJOO. These proteins are absent in healthy donors with non-inflamed muscle of the LES.Activated MMP-9 is detected in situ together with GAD65 and PNMA2 substrates.LIMITATIONSLIMITATIONS By its design, our study does not shed light on the mechanisms that induce the ectopic expression of the GAD65 and PNMA/Ta2 proteins in LES muscle tissue. It remains impossible to firmly state the sequence of events, e.g. whether the expression of ectopic antigens is due to tissue destruction or the presence of autoantibodies. Whether serum autoantibodies react with autoantigens of the LES muscle tissue of the patients with achalasia also remains unknown.IMPACTIMPACT This information yields new insights into pathophysiological mechanisms of achalasia for better disease understanding and possible design of novel therapeutic strategies.LAY SUMMARY Most of the achalasia sera have anti-GAD65 and anti-PNMA2. Esophageal tissues of achalasia patients have ectopic GAD65 and PNMA2. This information yields new insights into pathophysiological mechanisms of achalasia for better disease understanding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study has no financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was performed according to the principles expressed in the Declaration of Helsinki. The Research and Bioethics Committee of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran approved the study and written informed consent was obtained from all subjects (Ref. No. 1522).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Sharing Statement Furuzawa. Polymerized type I collagen for COVID-19 treatment. Data available: Yes Data types: Deidentified participant data How to access data: email jfuruzawa@gmail.com When available: beginning date: 01-01-2022 Supporting Documents Document types: None Additional Information Who can access the data: researchers whose proposed use of the data has been approved Types of analyses: for pre-planned analyses and meta-analyses (if applicable) Mechanisms of data availability: after approval of a proposal Any additional restrictions: n/a CMVcytomegalovirusDAB3,3’-diaminobenzidineEGJOOesophagogastric junction outflow obstructionGAD65glutamic acid decarboxylase of 65 kDaHBVhepatitis B virusHCVhepatitis C virusHIVhuman immunodeficiency virusHRMHigh-Resolution (Esophageal) ManometryHRPhorseradish peroxidaseLESlower esophageal sphincterMHCmajor histocompatibility complexMMPsmatrix metalloproteinasesPNMA2proteins in the nucleoli of the neuronal cell nuclei, Ma2/TaREGARemnant Epitopes Generate AutoimmunitySEMstandard error of the meanTDtransplant donors ER -